Market Overview

UPDATE: Canaccord Genuity Downgrades AVEO Pharmaceuticals to Hold Following ODAC Meeting

Related AVEO
EUSA Pharma, AVEO Announce Submission of Marketing Authorization Application to EMA for Tivozanib in Advanced Renal Cell Carcinoma
EXCLUSIVE: AVEO CEO Explains How New Partnership Will Address $500 Million Opportunity Overseas

In a report published Friday, Canaccord Genuity analyst Salveen Richter downgraded the rating on AVEO Pharmaceuticals (NASDAQ: AVEO) from Buy to Hold, and lowered the price target from $16.00 to $2.00.

In the report, Richter noted, “Following the FDA Oncologic Drug Advisory Committee (ODAC) meeting on tivozanib in renal cell carcinoma (RCC) where they voted 13 ‘no' – 1 ‘yes' (patient representative) on the question of ‘has the applicant demonstrated a favorable benefit to risk evaluation for treatment of RCC in an adequate and well-controlled trial?,' AVEO management hosted a very brief call (no Q&A) summarizing the panel outcome and stated they will impose a quiet period up to the July 28 PDUFA as they make decisions on the future of the company.”

AVEO Pharmaceuticals closed on Thursday at $2.65.

Latest Ratings for AVEO

May 2016Piper JaffrayInitiates Coverage onOverweight
Mar 2016FBR CapitalInitiates Coverage onOutperform
Mar 2015RBC CapitalUpgradesUnderperformSector Perform

View More Analyst Ratings for AVEO
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Downgrades Analyst Ratings


Related Articles (AVEO)

View Comments and Join the Discussion!